“It was a very, very interesting conversation and an acceptance that what you can’t see isn’t necessarily there.
Better health outcomes
“[Ngāti Whātua] holds a responsibility, every tribe in this country agrees, to manaaki all manuhiri who are in our tribal rohe. It benefits all in Ngāti Whātua and, in the rohe of Ngāti Whātua, others will benefit.
“We have no problems whatsoever that if Roche can work with Ngāti Whātua, Roche can work with Te Kahu o Taonui [Tai Tokerau tribe collective]. If they can with us, they can with anyone.”
Putting patients first, according to Roche Pharmaceuticals’ new NZ general manager Alex Muelhaupt, involves acknowledging the health disparities experienced by indigenous peoples.
“We believe that patients, communities and the biopharmaceutical industry must work together to ‘do now what patients and their whānau need next’.
“This is the purpose of our relationship commitment to Ngāti Whātua. By listening and walking with them, we can identify where our expertise can help with the better health outcomes they seek.”